Cor Vasa 2010, 52(9):543-561 | DOI: 10.33678/cor.2010.144

Stabilní angina pectoris. Doporučený diagnostický a léčebný postup České kardiologické společnosti

Jaromír Hradec1,*, Jan Bultas2, Michael Želízko3
1 III. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy
2 Ústav farmakologie, 3. lékařská fakulta Univerzity Karlovy
3 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Published: September 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradec J, Bultas J, Želízko M. Stabilní angina pectoris. Doporučený diagnostický a léčebný postup České kardiologické společnosti. Cor Vasa. 2010;52(9):543-561. doi: 10.33678/cor.2010.144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Niederle P, Staněk V. Zásady péče o nemocné s chronickými formami ICHS. Cor Vasa 1998;40:K69-K73.
    2. Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společná doporučení českých odborných společností. Cor Vasa 2005;47(9 Suppl.):3-14.
    3. Špinar J, Hradec J, Meluzín J, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007;49:K5-K34.
    4. Bytešník J. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005;47(9 Suppl.):41-57.
    5. Fiala M. Doporučené postupy pro diagnostiku a léčbu supraventrikulárních tachyarytmií. Cor Vasa 2005;47(9 Suppl.):18-39.
    6. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006;27:1341-1381. Go to original source... Go to PubMed...
    7. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic angina pectoris - summary article. J Am Coll Cardiol 2003;41:159-168.
    8. Pracovná skupina Slovenskej kardiologickej společnosti (koordinátor V. Fridrich). Odporúčania pre manažement stabilnej angíny pektoris. Cardiol 2003;12:281-311.
    9. Zdravotnictví České republiky 2008 ve statistických údajích. Praha: Ústav zdravotnických informací a statistiky, 2009 nebo www.uzis.cz.
    10. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972;29:154-163. Go to original source... Go to PubMed...
    11. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104-112. Go to original source... Go to PubMed...
    12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290:2805-2816. Go to original source... Go to PubMed...
    13. Diamond AG. A clinically relevant classification of chest discomfort. J Am Coll Cardiol 1983;1:574-575. Go to original source... Go to PubMed...
    14. Chaloupka V. Zátěžové testy v kardiologii. Zátěžová elektrokardiografie. Cor Vasa 2000;42:K54-K56.
    15. Daly C, Saravanan P, Fox K. Is calcium the clue? Eur Heart J 2002;23:1562-1565. Go to original source... Go to PubMed...
    16. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351: 2058-2068. Go to original source... Go to PubMed...
    17. Heart Outcome Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259. Go to original source...
    18. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-1275. Go to original source... Go to PubMed...
    19. Emond M, Monck MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-2657. Go to original source... Go to PubMed...
    20. Yusuf S, Wittes J, Friedman L. Overview of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. J Am Med Assoc 1988;260:2088-2093. Go to original source... Go to PubMed...
    21. Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009;10:1799-1817. Go to original source... Go to PubMed...
    22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study invetigators. N Engl J Med 2000;342:145-153. Go to original source...
    23. Fox K, on behalf of the EUROPA Executive Committee. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: a randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788. Go to original source... Go to PubMed...
    24. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. Go to original source... Go to PubMed...
    25. Fitzgerald AG. Coxibs and cardiovascular disease. N Engl J Med 2004;351: 1709-1711. Go to original source... Go to PubMed...
    26. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029. Go to original source... Go to PubMed...
    27. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F. Go to original source... Go to PubMed...
    28. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536. Go to original source... Go to PubMed...
    29. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816. Go to original source... Go to PubMed...
    30. Tardif JC, Ponikowski P, Kahan T. Efficacy of the current I(f) inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30:540-548. Go to original source... Go to PubMed...
    31. Fox K, Ford I, Steg G, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30: 2185-2194. Go to original source... Go to PubMed...
    32. Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23: 641-648. Go to original source... Go to PubMed...
    33. Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol 2005;98:79-89. Go to original source... Go to PubMed...
    34. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coronary Artery Dis 2003;14:171-179. Go to original source... Go to PubMed...
    35. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847. Go to original source...
    36. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007;50:1299-1304. Go to original source... Go to PubMed...
    37. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640. Go to original source... Go to PubMed...
    38. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115. Go to original source... Go to PubMed...
    39. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362: 1093-1099. Go to original source... Go to PubMed...
    40. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42. Go to original source... Go to PubMed...
    41. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794. Go to original source... Go to PubMed...
    42. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947. Go to original source... Go to PubMed...
    43. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. J Am Med Assoc 2006;295:1253-1263. Go to original source... Go to PubMed...
    44. Grube E, Dawkins KD, Guagliumi G, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-2582. Go to original source... Go to PubMed...
    45. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents (BASKET-LATE). J Am Coll Cardiol 2006;48:2584-2591. Go to original source... Go to PubMed...
    46. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019. Go to original source... Go to PubMed...
    47. Luchi RJ, Scott SM, Deupree RH, and The Principal Investigators and their Associates of the Veterans Administration Cooperative Study. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration cooperative study. N Engl J Med 1987;316: 977-984. Go to original source... Go to PubMed...
    48. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982;2(8309):173-180.
    49. Principal Investigators of CASS and their Associates. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS). Circulation 1981;63(Suppl. I):I1-I81.
    50. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-2912. Go to original source... Go to PubMed...
    51. Boden WE, O'Rourke RA, Teo KK. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516. Go to original source... Go to PubMed...
    52. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-918. Go to original source... Go to PubMed...
    53. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346: 1184-1189. Go to original source... Go to PubMed...
    54. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225. Go to original source... Go to PubMed...
    55. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124. Go to original source... Go to PubMed...
    56. SOS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002;360:965-970. Go to original source... Go to PubMed...
    57. Serruys PW, Ong AT, Morice MC, et al. Arterial Revascularisation Therapies Study Part II: sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 2005;1:147-156. Go to PubMed...
    58. Serruys PW, Morice MC, Kappetein AP. Percutaneous coronary intervention versus coronary atrery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes